Outcomes of Turkish Ankylosing Spondylitis Patients

Abstract

Ankylosing spondylitis (AS) is chronic, progressive, systemic inflammatory rheumatic diseases that lead to serious disability. The objective of this study was to determine the demographic, clinic characteristics and CYP2D6*4 gene mutation profiles of the AS patients in Tokat, Turkey. In this retrospective study, we evaluated 103 patients that were diagnosed and followed up as AS in Tokat, Turkey between 2008-2011. Demographical properties (age, sex, education level, age at diagnosis, disease duration), clinical characteristics (HLA27, peripheral/extraarticular involvoment, chest expansion, enthesopathy, modified schouber) and genetic analysis results (CYP2D6*4 gene mutation frequency) of AS patients were assessed. The mean age of AS patients was 36.80±9.25 years. The mean age of female and male 39.10±7.89, 35.40± 9.79 respectively. The female to male ratio was 1:1.6. Major histocompatibility complex, class I, B 27 (HLAB27) was investigated and the rate of positivity was 73.78 %. There was a statistically significant difference between CYP2D6 gene mutation and peripheral /extraarticular involvement (p

Keywords

• Ankylosing spondylitis, CYP2D6 gene, clinical characteristics

Outcomes of Turkish Ankylosing Spondylitis Patients

Öz

Ankilozan Spondilit (AS) kronik, ilerleyici, sistemik, inflamatuvar ve yetersizliğe yol açan romatizmal bir hastalıktır. Bu çalışmanın amacı, Tokat bölgesindeki AS’li hastaların demografik, klinik özelliklerini ve CYP2D6*4 gen mutasyon profilini belirlemektir. Bu çalışmada, Tokat bölgesinde 2008-2011 yılları arasında teşhis ve tedavi edilen 103 AS’li hastanın demografik özellikleri (yaş, cinsiyet, eğitim düzeyi, tanı yaşı, hastalık süresi), klinik özellikleri (HLA27, periferik eklem ve extraartiküler tutulum, göğüs ekspansiyonu, entesopati, modifiye schouber) ve genetik analiz sonuçları (CYP2D6*4 gen mutasyon sıklığı) değerlendirildi. AS’li hastaların yaş ortalaması 36.80±9.25 yıl idi. Kadın ve erkek hastaların ortalama yaşları sırası ile 39.10±7.89, 35.40± 9.79 yıl olarak saptandı. Kadın/erkek oranı 1:1.6 idi. Major histokompatibilite kompleksi, sınıf I, B 27 (HLAB27) incelendi ve pozitiflik oranı 73.78 % olarak belirlendi. CYP2D6 gene mutasyonu ve periferal/extraartiküler tutulum arasında istatistiksel olarak anlamlı farklılık saptandı (p<0.05). AS gibi romatolojik hastalıkların klinik özelliklerini ve CYP2D6*4 gen mutasyonunu belirleme hastalığın erken tanı, tedavi ve sonucu açısından kayda değer yararlar sağlayabilir

Anahtar Kelimeler

• Ankilozan spondilit, CYP2D6 geni, klinik özellikler

References

1. Bodur H, Ataman Ş, Akbulut L, et al. Characteristics and medical management of patients with rheumatoid ar- thritis and ankylosing spondylitis. Clin Rheumatol 2008; 27:1119-25.
2. Çağlar NS, Burnaz O, Akın T, et al. Demographic and clinical properties and medical treatments of patients followed as ankylosing spondylitis. Istanbul Med J 2011;12:19-24.
3. Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008;35:305-9.
4. Erden G, Acar FS, Inal EE, et al. Frequency of mutated allele CYP2D6*4 in the Turkish ankylosing spondylitis pa- tients and healthy controls. Rheumatol Int 2009;29:1431- 34.
5. Van der Linden S, Vonder Heide D, Braun J. Ankylosing spondylitis. In: Harris ED, editor. Kelley’s textbook of rheumatology 2006; 7th ed. p.1125–38.
6. Dean AG, Sullivan KM, Soe MM. OpenEpi. “Open Source Epidemiologic Statistics for Public Health,” Version 2.3.1. www.OpenEpi.com, updated 2010/19/09, accessed 2011/02/21.
7. Bodur H, Ataman S, Rezvani A, et al. Quality of life and related variables in patients with ankylosing spondylitis Qual Life Res 2011;20:543-9.
8. Baraliakos X, Braun J. Spondyloarthritides Best Practice & Research Clinical Rheumatology 2011;25:825-42.

9. Uppal SS, Abraham M, Chowdhury RI et al. Ankylosing spondylitis and undifferentiated spondyloarthritis in Kuwait: a comparison between Arabs and South Asians. Clin Rheumatol 2006;25:219-24.
10. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535-43.
11. Zink A, Listing J, Niewerth M, et al. The national data- base of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60:207–13.
12. Baek HJ, Shin KC, Lee YJ et al. Clinical features of adul- tonset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spi- nal disease course than those without PJD. Rheumatology 2004;43:1526-31.
13. Oniankitan O, Ranaivo N, Carton L et al. Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patients. J Rheumatol 2005;32:77-9.
14. Braun J, Zochling J, Baraliakos X, et al. Efficacy of sul- fasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65:1147–53.
15. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247–55.
16. Laval SH, Timms A, Edwards S, et al. Whole-genome screen- ing in ankylosing spondylitis: evidence of non-MHC genetic- susceptibility loci. Am J Human Gen 2001;68:918–26.
17. Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spon- dylitis. Annals of the Rheumatic Diseases 2000;59:883–6.
18. Wu W, Ding Y, Chen Y, et al. Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms. Rheumatol Int 2012;32:2517-21.